8-K: Palvella Reports Positive Phase 2 QTORIN Results for cVMs

Palvella Therapeutics announced positive topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for cutaneous venous malformations.

Summary

• Palvella Therapeutics announced positive topline results from its Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of cutaneous venous malformations (cVMs).
• The study achieved statistical significance (p<0.05) on multiple pre-specified clinician-reported and patient-reported efficacy endpoints.
• The mean effect size at Week 12 for the Overall Cutaneous Venous Malformations Investigators Global Assessment (cVM-IGA) was +1.5 (p<0.001).
• 73% of participants (11 out of 15) demonstrated a 1-point improvement or greater on the Overall cVM-IGA at Week 12.
• 67% of participants (10 out of 15) were rated as either 'Much Improved' (+2) or 'Very Much Improved' (+3) on the Overall cVM-IGA at Week 12.
• QTORIN rapamycin was generally well-tolerated, consistent with previous clinical trials, with the most common treatment-emergent adverse events being application site reactions (erythema, 25%).
• No drug-related serious adverse events were reported, and rapamycin levels in systemic circulation were below the lower limit of quantification (2 ng/mL) for all participants.
• The company plans near-term discussions with the FDA in early 2026 regarding the potential for Breakthrough Therapy Designation and a Phase 3 pivotal study.

Sentiment

Score: 9

Explanation: The filing reports overwhelmingly positive topline results from a Phase 2 clinical trial, demonstrating statistical significance across multiple efficacy endpoints and a high response rate in a disease with no FDA-approved therapies. The drug was well-tolerated, and the company plans to pursue Breakthrough Therapy Designation and a Phase 3 study, indicating strong progress towards commercialization.

Positives

• Achieved statistical significance (p<0.05) on multiple pre-specified clinician-reported and patient-reported efficacy endpoints, including dynamic change and static severity scales.
• Mean effect size of +1.5 (p<0.001) at Week 12 on the Overall Cutaneous Venous Malformations Investigator Global Assessment (cVM-IGA).
• 73% of participants (11/15) demonstrated a 1-point improvement or greater on the Overall cVM-IGA at Week 12, exceeding the internal threshold to progress to Phase 3 (~30%).
• 67% of participants (10/15) were rated as either 'Much Improved' (+2) or 'Very Much Improved' (+3) on the Overall cVM-IGA at Week 12.
• Statistically significant improvements observed on dynamic change scales for cVM-IGA Height/Engorgement (+1.3, p<0.001), cVM-IGA Appearance (+1.5, p<0.001), cVM-IGA Bleeding (+0.7, p=0.045), and Overall Patient Global Impression of Change (PGI-C) (+1.1, p<0.001).
• Statistically significant improvements on key static severity scales: Overall Clinician Global Impression of Severity (CGI-S) (-1.0, p<0.001), cVM-MCSS Severity of Height/Engorgement (-1.3, p<0.001), cVM-MCSS Severity of Appearance (-1.1, p<0.001), and Overall Patient Global Impression of Severity (PGI-S) (-0.5, p=0.027).
• QTORIN rapamycin was generally well-tolerated, similar to previous clinical trials, with all treatment-related adverse events being moderate or mild and no drug-related serious adverse events.
• Rapamycin levels were below the lower limit of quantification (2 ng/mL) in systemic circulation for all participants, significantly below the 5 ng/mL threshold for immunosuppressive effects.
• The FDA previously granted Fast Track Designation to QTORIN rapamycin for venous malformations.
• The company does not anticipate requiring confirmed genotypes or genetic testing in future studies, potentially broadening the eligible patient population.

Risks

• Competition in the market for rare skin disease therapies.
• Ability to grow and manage growth, maintain relationships with suppliers, and retain management and key employees.
• Success, cost, and timing of product development activities, studies, and clinical trials.
• Changes in applicable laws or regulations.
• Adverse effects from other economic, business, or competitive factors.
• Estimates of expenses and profitability may not be accurate.
• Evolution of the markets in which the company competes.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property.
• Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially.
• Data and results from clinical studies may not necessarily be indicative of future results.
• Limited experience in designing and conducting clinical trials.
• Ability to identify and pivot to other programs, product candidates, or indications that may be more profitable or successful.
• Reliance on third parties, contract manufacturers, and contract research organizations.
• Negative impacts of global events on operations, including ongoing and planned clinical trials and preclinical studies.
• Ability to attract, hire, and retain skilled executive officers and employees.

Future Outlook

Palvella plans near-term discussions with the FDA in early 2026 to pursue Breakthrough Therapy Designation and a Phase 3 pivotal study for QTORIN rapamycin for cutaneous venous malformations, also exploring the newly announced Plausible Mechanism Pathway. The company believes QTORIN rapamycin has the potential to become the first FDA-approved therapy and standard of care for the estimated more than 75,000 individuals with cVMs in the U.S. The Phase 2 results further support Palvella's pipeline-in-a-product strategy for QTORIN rapamycin, with programs advancing in microcystic LMs, cVMs, and angiokeratomas, and QTORIN pitavastatin for disseminated superficial actinic porokeratosis.

Management Comments

• "Based on the large magnitude of the treatment effect observed in the majority of patients in the Phase 2 TOIVA study, QTORIN rapamycin has potential to become first-line therapy and to establish a much-needed standard of care for individuals living with cutaneous venous malformations." Megha Tollefson, M.D., pediatric dermatologist at Mayo Clinic and Principal Investigator of the Phase 2 TOIVA study.
• "Cutaneous venous malformations are congenital, chronic, progressive lesions that persist throughout life and can have a profound impact on patients quality of life. They may affect functionally critical areas of the body, often leading to daily discomfort, limitations in activities, and substantial burden for patients and their families. Current procedure-based approaches can be painful, ineffective, or both, and result in high rates of recurrence." Megha Tollefson, M.D.
• "Based on the strength of the Phase 2 TOIVA results, including the 73% of participants who improved on the Overall cVM-IGA at Week 12, Palvella is planning for near-term discussions with FDA regarding the potential for Breakthrough Therapy Designation and a Phase 3 pivotal study, as well as the newly announced Plausible Mechanism Pathway." Wes Kaupinen, Founder and Chief Executive Officer of Palvella.
• "These data reinforce our conviction in the therapeutic potential of QTORIN rapamycin, the strength of the QTORIN platform, and our long-term vision to become the leading rare disease company focused on developing and commercializing novel therapies for patients with serious, rare skin diseases." Wes Kaupinen.

Industry Context

Cutaneous venous malformations (cVMs) are a rare genetic disease affecting an estimated over 75,000 patients in the U.S., characterized by dysfunctional veins within the skin due to mutations causing overactivation of the PI3K/mTOR signaling pathway. This condition presents a significant unmet medical need as there are currently no FDA-approved therapies. Existing treatments, such as sclerotherapy and laser surgery, are invasive, often ineffective, and do not address the underlying causal biology, leading to high rates of recurrence. QTORIN rapamycin, as a targeted topical therapy, represents a potential first-in-disease treatment that could establish a new standard of care.

Comparison to Industry Standards

• There are currently no FDA-approved therapies for cutaneous venous malformations, positioning QTORIN rapamycin as a potential first-in-class treatment.
• Existing procedure-based approaches like sclerotherapy and laser surgery are non-specific, highly invasive, traumatic, and often result in limited, short-term improvement and high recurrence rates, failing to address the underlying causal biology of the disease.
• Real-world evidence supports rapamycin's off-label use for primarily internal manifestations of venous malformations, but poor patient outcomes persist in cutaneous disease, highlighting the need for a targeted topical therapy like QTORIN.

Stakeholder Impact

• **Patients**: Significant positive impact due to the potential for the first FDA-approved, targeted, localized therapy for cutaneous venous malformations, addressing a high unmet medical need and potentially improving quality of life and functional impairment.
• **Shareholders**: Highly positive impact due to strong clinical trial results, potential for Breakthrough Therapy Designation, and advancement towards a Phase 3 pivotal study, which could significantly increase company valuation and market opportunity.
• **Employees**: Positive impact from successful clinical development, reinforcing the company's strategic vision and pipeline, potentially leading to increased job security and growth opportunities.
• **Regulatory Authorities**: Engagement with FDA for Breakthrough Therapy Designation and Phase 3 planning, potentially leading to a new approved therapy for a rare disease.

Next Steps

• Near-term discussions with FDA in early 2026 regarding potential for Breakthrough Therapy Designation for QTORIN rapamycin for cVMs.
• Near-term discussions with FDA in early 2026 regarding a Phase 3 pivotal study for QTORIN rapamycin for cVMs.
• Discussions with FDA regarding the newly announced Plausible Mechanism Pathway.
• Continue efforts to collect genetic data on trial participants.
• Presentation of genotype-stratified results at future medical meetings.
• Advance other QTORIN rapamycin programs, including those for microcystic lymphatic malformations (LMs) and angiokeratomas.
• Continue development of QTORIN pitavastatin for the topical treatment of disseminated superficial actinic porokeratosis.

Key Dates

Recommendation

The positive Phase 2 topline results for QTORIN rapamycin in cutaneous venous malformations are highly significant, demonstrating statistical significance across multiple endpoints and a high patient response rate in a disease with no FDA-approved therapies. The drug's favorable safety profile and the company's intent to pursue Breakthrough Therapy Designation and a Phase 3 pivotal study position it strongly for future regulatory success and market leadership. This represents a major de-risking event for the asset and the company's pipeline-in-a-product strategy, indicating substantial upside potential for investors.

Keywords

Palvella Therapeutics, QTORIN, rapamycin, cutaneous venous malformations, cVM, Phase 2, TOIVA study, rare skin diseases, biopharmaceutical, clinical trial, FDA, Breakthrough Therapy Designation, Fast Track Designation, mTOR inhibitor, genetic disease, vascular malformations